Related Experiment Videos
Erythrocyte complement receptor type 1 in patients with systemic lupus erythematosus
1Department of Internal Medicine, Kaohsiung Medical College, Taiwan, Republic of China.
The Journal of Rheumatology
|October 1, 1989
Summary
Erythrocyte complement receptor type 1 (CR1) is lower in systemic lupus erythematosus (SLE) patients and correlates with disease activity. This acquired deficiency may influence SLE development and severity.
Area of Science:
- Immunology
- Rheumatology
- Clinical Medicine
Background:
- Complement receptor type 1 (CR1) on erythrocytes plays a role in immune complex clearance.
- Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune complex deposition.
- Reduced erythrocyte CR1 levels have been observed in various autoimmune conditions.
Purpose of the Study:
- To investigate erythrocyte CR1 levels in patients with SLE.
- To determine the correlation between erythrocyte CR1 levels and SLE disease activity.
- To explore the relationship between erythrocyte CR1, circulating immune complexes, and complement components in SLE.
Main Methods:
- Erythrocyte CR1 levels were quantified in 71 SLE patients and 43 healthy controls.
- Disease activity was assessed in SLE patients.
- Levels of circulating immune complexes (CIC), C3, CH50, factor B, and factor H were measured.
Main Results:
- SLE patients exhibited significantly lower erythrocyte CR1 levels compared to controls.
- Erythrocyte CR1 levels were inversely correlated with CIC and positively correlated with C3, CH50, factor B, and factor H.
- A higher incidence of lupus nephritis was observed in SLE patients with decreased erythrocyte CR1.
Conclusions:
- The deficiency of erythrocyte CR1 in SLE is likely acquired.
- Erythrocyte CR1 levels serve as a potential marker for SLE clinical disease activity.
- Reduced erythrocyte CR1 may contribute to the pathogenesis of SLE.